Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the AIM-listed clinical-stage biopharmaceutical company, has appointed Dr Adrian Kilcoyne to its Scientific Advisory Board, bringing more than 20 years of oncology and immunology drug development experience to the company. Kilcoyne is currently chief medical officer at Cellectis, the French biotechnology company focused on allogeneic CAR-T therapies, which engineer a patient's immune cells to target and destroy cancer.